<DOC>
	<DOCNO>NCT02846493</DOCNO>
	<brief_summary>This prospective , randomize , control clinical trial evaluate effect security dexamethasone prevention Patients Ovarian Hyperstimulation Syndrome .</brief_summary>
	<brief_title>Efficacy Safety Dexamethasone Prevention Patients Ovarian Hyperstimulation Syndrome</brief_title>
	<detailed_description>Ovarian hyperstimulation syndrome ( OHSS ) iatrogenic complication ovarian stimulation , severe form associate significant morbidity life threaten . It characterize cystic enlargement ovary rapid fluid shift intravascular compartment third space . It think increase vascular permeability pivotal mechanism OHSS pathophysiology . The administration human chorionic gonadotrophin result release vasoactive substance vascular endothelial growth factor cause vasodilation leakage fluid . Glucocorticoids synthetic derivative inhibitory effect VEGF gene expression vascular smooth muscle cell . By reduce leukocytic infiltration release inflammatory mediator , inhibit vasodilation prevent increase vascular permeability , agent dampen inflammatory response prevent edema formation , thus offer potential therapeutic intervention OHSS . Investigators observe hundred patient clinical practice low-dose dexamethasone prevention action patient IVF cycle high risk OHSS . This clinical trial design evaluate effect security dexamethasone prevention patient Ovarian Hyperstimulation Syndrome . There two group : bromocriptine group , dexamethasone group .After followed-up 7 day , Clinical OHSS parameter collect oocyte retrieval 4rd 6th treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Women reproductive age Women control ovarian hyperstimulation part assist reproductive technique Women risk severe OHSS ( serum estradiol level &gt; 3000pg/ml day HCG trigger ; retrieval 20 oocyte ) Unwillingness comply study protocol . Attending clinical trial period . Chronic glucocorticoid synthetic derivative intake . History allergic study medication . The patient take dexamethasone.ï¼š hypertension , diabetes , gastric ulcer ; abnormal renal hepatic function .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Ovarian hyperstimulation syndrome</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>